Most interesting part of the 10K ---> Target
Post# of 15624
(Total Views: 472)
Posted On: 04/17/2017 6:51:16 PM
Most interesting part of the 10K --->
Target Indication @ Collaborator & Current Status
Multiple Myeloma @ Sheba Academic Medical Center
● Entered into a research agreement for in vitro studies
● Negotiating terms of a research agreement for in vivo studies
● Completed one in vitro study
● Proceeding with further pre-clinical in vitro studies (safety and toxicity, pharmacokinetic, and pharmacodynamic)
● Expect to submit a clinical trial protocol to the Israeli Institutional Review Board and received its approval to commence a clinical study
● Intend to commence a clinical study in the third quarter of 2017
● Drafted a clinical trial protocol synopsis, which we believe will assist us in preparing an application for orphan status designation
Psoriasis @ Sheba Academic Medical Center
● Entered into a Research Collaboration and License Agreement but have not commenced any studies to date
● Received an IRB approval for a Phase I, double blind, randomized, placebo controlled, multiple escalating dose study to determine the safety, tolerability and pharmacokinetic profile of medical grade cannabis in healthy volunteers. The study should begin in or about April 2017.
Psoriasis @ Emilia Cosmetics Ltd.
● Entered into a nonbinding memorandum of understanding for the development, manufacture and marketing of a cannabinoid-based topical cream
● We finished the development of the topical cream in the first quarter of 2016.
Fibromyalgia @ Sheba Academic Medical Center
● Drafted a clinical trial protocol synopsis
New delivery system - cannabis soluble tablet G.C. Group Ltd.
Completed a proof of concept (the R=Research phase) of the desired end-product (the soluble tablet) to test the fabric, durability, solidification and other features of the cannabis soluble tablet. This arrangement was terminated effective on December 31, 2015. Company has plans to continue development.
Target Indication @ Collaborator & Current Status
Multiple Myeloma @ Sheba Academic Medical Center
● Entered into a research agreement for in vitro studies
● Negotiating terms of a research agreement for in vivo studies
● Completed one in vitro study
● Proceeding with further pre-clinical in vitro studies (safety and toxicity, pharmacokinetic, and pharmacodynamic)
● Expect to submit a clinical trial protocol to the Israeli Institutional Review Board and received its approval to commence a clinical study
● Intend to commence a clinical study in the third quarter of 2017
● Drafted a clinical trial protocol synopsis, which we believe will assist us in preparing an application for orphan status designation
Psoriasis @ Sheba Academic Medical Center
● Entered into a Research Collaboration and License Agreement but have not commenced any studies to date
● Received an IRB approval for a Phase I, double blind, randomized, placebo controlled, multiple escalating dose study to determine the safety, tolerability and pharmacokinetic profile of medical grade cannabis in healthy volunteers. The study should begin in or about April 2017.
Psoriasis @ Emilia Cosmetics Ltd.
● Entered into a nonbinding memorandum of understanding for the development, manufacture and marketing of a cannabinoid-based topical cream
● We finished the development of the topical cream in the first quarter of 2016.
Fibromyalgia @ Sheba Academic Medical Center
● Drafted a clinical trial protocol synopsis
New delivery system - cannabis soluble tablet G.C. Group Ltd.
Completed a proof of concept (the R=Research phase) of the desired end-product (the soluble tablet) to test the fabric, durability, solidification and other features of the cannabis soluble tablet. This arrangement was terminated effective on December 31, 2015. Company has plans to continue development.
(2)
(0)